COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving the Th1/Th17 pathway. The primary objective of this study was to assess the impact of itolizumab in arresting the lung function deterioration of COVID‐19 patients. Secondary objectives included safety, duration of ventilation, 14‐day mortality and evaluation of interleukin 6 concentration.

中文翻译：

---

用抗 CD6 抗体 itolizumab 治疗 COVID-19 患者

COVID-19 可导致过度炎症状态。CD6 是一种在成熟 T 淋巴细胞上表达的糖蛋白，是 T 细胞活化的关键调节因子。Itolizumab 是一种靶向 CD6 的人源化抗体。自身免疫性疾病的非临床和临床数据表明，它降低了主要涉及 Th1/Th17 通路的多种细胞因子。本研究的主要目的是评估 itolizumab 在阻止 COVID-19 患者肺功能恶化方面的影响。次要目标包括安全性、通气时间、14 天死亡率和白细胞介素 6 浓度评估。